Health Care & Life Sciences » Biotechnology | Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,105
2,820
4,104
4,860
5,872
6,711
Cost of Goods Sold (COGS) incl. D&A
197
258
468
404
543
582
Gross Income
1,908
2,562
3,636
4,456
5,330
6,129
SG&A Expense
1,148
1,723
2,384
3,125
3,250
3,594
EBIT
761
838
1,252
1,331
2,080
2,534
Unusual Expense
3
32
19
10
30
42
Non Operating Income/Expense
-
1
-
16
54
89
Interest Expense
46
37
14
7
25
28
Pretax Income
713
776
1,225
1,330
2,079
2,554
Income Tax
289
428
589
434
880
109
Consolidated Net Income
424
348
636
896
1,199
2,444
Net Income
424
348
636
896
1,199
2,444
Net Income After Extraordinaries
424
348
636
896
1,199
2,444
Net Income Available to Common
424
348
636
896
1,199
2,444
EPS (Basic)
3.81
3.07
5.52
7.70
10.34
21.29
Basic Shares Outstanding
98
101
103
105
106
108
EPS (Diluted)
3.81
3.07
5.52
7.70
10.34
21.29
Diluted Shares Outstanding
111
113
115
116
116
115
EBITDA
802
891
1,327
1,435
2,225
2,683
Non-Operating Interest Income
3
6
6
-
-
-

About Regeneron Pharmaceuticals

View Profile
Address
777 Old Saw Mill River Road
Tarrytown New York 10591
United States
Employees -
Website http://www.regeneron.com
Updated 07/08/2019
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.